PharmacoEconomics

, Volume 27, Issue 4, pp 267–279

Economic and Human Costs of Restless Legs Syndrome

  • Thomas Reinhold
  • Falk Müller-Riemenschneider
  • Stefan N. Willich
  • Bernd Brüggenjürgen
Leading Article

Abstract

Restless legs syndrome (RLS) is a common and often underestimated neurological disorder, with a prevalence ranging from approximately 2.5% to 10% in Western industrialized countries. The aim of the present study was to summarize the research findings on the human and economic costs associated with RLS in populations without any co-morbidities or potentially confounding health conditions. A further objective was to identify studies on the cost effectiveness of RLS treatments.

A systematic literature search was performed. Two researchers independently assessed the relevance of each publication. Studies published before August 2008 were included if they assessed quality of life in patients suffering from RLS, determined total or patient-related costs attributable to RLS, and/or evaluated the cost effectiveness of treatment options for RLS.

A total of 725 references were identified, including 100 full-text articles. Fifteen of these publications met all of the selection criteria and were included in the present review. Seven abstracts that focused on the economic burden of RLS and/or the cost effectiveness of different treatment strategies in RLS patients were also included.

RLS was associated, in the included studies, with reductions in quality of life similar to those seen in patients with other chronic conditions. The cost-of-illness studies were heterogeneous but indicated that RLS was associated with a substantial economic burden, resulting in high direct and indirect costs to society. Although effective and cost-effective treatments appear to be available, further research is warranted, especially regarding the economic burden of RLS and the cost effectiveness of available treatment options.

Supplementary material

40273_2012_27040267_MOESM1_ESM.pdf (105 kb)
Supplementary material, approximately 107 KB.

References

  1. 1.
    Hornyak M. Restless legs syndrome. Med Welt 2007 Oct; 58 (10): 499–503Google Scholar
  2. 2.
    Garcia-Borreguero D, Egatz R, Winkelmann J, et al. Epidemiology of restless legs syndrome: the current status. Sleep Med Rev 2006 Jun; 10 (3): 153–67PubMedCrossRefGoogle Scholar
  3. 3.
    Jones HJ, Derodra JK. Restless legs syndrome: a review. Euro J Vasc Endovasc Sur 1997 Dec; 14 (6): 430–2CrossRefGoogle Scholar
  4. 4.
    Spiegelhalder K, Hornyak M. Restless legs syndrome in older adults. Clin Geriatr Med 2008 Feb; 24 (1): 167–80PubMedCrossRefGoogle Scholar
  5. 5.
    Gomez-Esteban JC, Zarranz JJ, Tijero B, et al. Restless legs syndrome in Parkinson’s disease. Mov Disord 2007 Oct; 22 (13): 1912–6PubMedCrossRefGoogle Scholar
  6. 6.
    Suzuki K, Ohida T, Sone T, et al. The prevalence of restless legs syndrome among pregnant women in Japan and the relationship between restless legs syndrome and sleep problems. Sleep 2003 Sep; 26 (6): 673–7PubMedGoogle Scholar
  7. 7.
    Kavanagh D, Siddiqui S, Geddes CC. Restless legs syndrome in patients on dialysis. Am J Kidney Dis 2004 May; 43 (5): 763–71PubMedCrossRefGoogle Scholar
  8. 8.
    Chasens ER. Understanding sleep in persons with diabetes. Diabetes Educ 2007 May; 33 (3): 435–6PubMedCrossRefGoogle Scholar
  9. 9.
    Merlino G, Fratticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep 2007 Jul; 30 (7): 866–71PubMedGoogle Scholar
  10. 10.
    Manconi M, Fabbrini M, Bonanni E, et al. High prevalence of restless legs syndrome in multiple sclerosis. Eur J Neurol 2007 May; 14 (5): 534–9PubMedCrossRefGoogle Scholar
  11. 11.
    Mathis J. Update on restless legs. Swiss Med Wkly 2005 Dec; 135 (47–48): 689–96Google Scholar
  12. 12.
    Castillo PR, Kaplan J, Lin SC, et al. Prevalence of restless legs syndrome among native South Americans residing in coastal and mountainous areas. Mayo Clin Proc 2006 Oct; 81 (10): 1345–7PubMedCrossRefGoogle Scholar
  13. 13.
    Sevim S, Dogu O, Camdeviren H, et al. Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey. Neurology 2003 Dec; 61 (11): 1562–9PubMedCrossRefGoogle Scholar
  14. 14.
    Tan EK, Seah A, See SJ, et al. Restless legs syndrome in an Asian population: a study in Singapore. Mov Disord 2001 May; 16 (3): 577–9PubMedCrossRefGoogle Scholar
  15. 15.
    Vignatelli L, Billiard M, Clarenbach P, et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006 Oct; 13 (10): 1049–65PubMedCrossRefGoogle Scholar
  16. 16.
    Reese JP, Stiasny-Kolster K, Oertel WH, et al. Health-related quality of life and economic burden in patients with restless legs syndrome. Exp Rev Pharmacoeconomics Outcomes Res 2007 Oct; 7 (5): 503–21CrossRefGoogle Scholar
  17. 17.
    Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004 Jun; 26 (6): 925–35PubMedCrossRefGoogle Scholar
  18. 18.
    Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005 Jun; 165 (11): 1286–92PubMedCrossRefGoogle Scholar
  19. 19.
    Baggen M, Timmermans M, Moes K, et al. Prevalence and impact of restless legs syndrome (RLS) in primary care. Huisarts Wet 2007 Apr; 50 (4): 134–9CrossRefGoogle Scholar
  20. 20.
    O’Keeffe ST, Egan D, Myers A, et al. The frequency and impact of restless legs syndrome in primary care. Ir Med J 2007; 100 (7): 539–42PubMedGoogle Scholar
  21. 21.
    Kushida C, Martin M, Nikam P, et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007 May; 16 (4): 617–24PubMedCrossRefGoogle Scholar
  22. 22.
    Happe S, Reese JP, Stiasny-Kolster K, et al. Assessing health-related quality of life in patients with restless legs syndrome. Sleep Med. Epub 2008 Mar 21Google Scholar
  23. 23.
    Lee HB, Hening WA, Allen RP, et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci 2008 Dec; 20 (1): 101–5PubMedCrossRefGoogle Scholar
  24. 24.
    Rothdach AJ, Trenkwalder C, Haberstock J, et al. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Neurology 2000 Mar; 54 (5): 1064–8PubMedCrossRefGoogle Scholar
  25. 25.
    Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006 Oct; 7 (7): 545–52PubMedCrossRefGoogle Scholar
  26. 26.
    Cuellar NG, Strumpf NE, Ratcliffe SJ. Symptoms of restless legs syndrome in older adults: outcomes on sleep quality, sleepiness, fatigue, depression, and quality of life. J Am Geriatr Soc 2007 Sep; 55 (9): 1387–92PubMedCrossRefGoogle Scholar
  27. 27.
    Gerhard R, Bosse A, Uzun D, et al. Quality of life in restless legs syndrome: influence of daytime sleepiness and fatigue. Med Klin 2005 Nov; 100 (11): 704–9CrossRefGoogle Scholar
  28. 28.
    McCrink L, Allen RP, Wolowacz S, et al. Predictors of health-related quality of life in sufferers with restless legs syndrome: a multi-national study. Sleep Med 2007 Jan; 8 (1): 73–83PubMedCrossRefGoogle Scholar
  29. 29.
    Phillips B, Young T, Finn L, et al. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000 Jul; 160 (14): 2137–41PubMedCrossRefGoogle Scholar
  30. 30.
    Curtice TG, Long SR, Baser O, et al. Economic burden of restless legs syndrome in a privately-insured population [abstract]. Value Health 2008; 9 (3): A85CrossRefGoogle Scholar
  31. 31.
    Douzinas N, Connolly MP, Kirsch J, et al. Establishing the indirect costs of RLS based on severity using the International Restless Legs Severity rating scale (IRLS) and the productivity and activity impairment [abstract]. Eur J Neurol 2005; 12 (s2): A376Google Scholar
  32. 32.
    Maurel F, Girard B, Crochard A, et al. Profile of patients suffering from restless legs syndrome and estimation of their annual cost in a ambulatory care setting [abstract]. Value Health 2004; 7 (1): 790–1CrossRefGoogle Scholar
  33. 33.
    Eisensehr I, Möller C, Köster J, et al. Effectiveness of pramipexole in the treatment of RLS and the effect on work productivity: a 12-weeks non-interventional trial in patients with primary restless legs syndrome (RLS) [abstract]. Value Health 2007; 10 (6): A393CrossRefGoogle Scholar
  34. 34.
    Beard AJ. Examination of cost-effectiveness of dopamine agonists for the treatment of restless legs syndrome [abstract]. Value Health 2006; 9 (3): A81CrossRefGoogle Scholar
  35. 35.
    Lees M, Roberts G, Tabberer M, et al. Cost-effectiveness of treating restless legs patients with pramipexole compared to no treatment in Sweden [abstract]. Value Health 2006; 9 (6): A376CrossRefGoogle Scholar
  36. 36.
    Moore AP, Lloyd A, Scott DA, et al. The cost-effectiveness of treating patients with restless legs syndrome (RLS) using ropinirole [abstract]. Value Health 2004; 7 (6): A791CrossRefGoogle Scholar
  37. 37.
    Lees M, Roberts G, Tabberer M, et al. Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden. Curr Med Res Opin 2008 Oct; 24 (10): 2919–30PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Thomas Reinhold
    • 1
  • Falk Müller-Riemenschneider
    • 1
  • Stefan N. Willich
    • 1
  • Bernd Brüggenjürgen
    • 1
  1. 1.Institute for Social Medicine, Epidemiology and Health EconomicsCharité University Medical CenterBerlinGermany

Personalised recommendations